SCGN and early-onset autosomal dominant Alzheimer disease: Previous studies suggested that secretagogin is neuroprotective in hippocampal pyramidal cells in Alzheimer’s disease (Attems et al. 2008) and secretagogin expression has recently been shown to parallel disease progression: P301L tau transgenic mice showed reduced secretagogin expression in hippocampal neurons (Attems et al. 2011).